RAY DEBANJAN 4
4 · CytomX Therapeutics, Inc. · Filed Oct 2, 2018
Insider Transaction Report
Form 4
RAY DEBANJAN
Chief Financial Officer
Transactions
- Sale
Common Stock
2018-10-01$18.46/sh−3,000$55,380→ 5,928 total - Exercise/Conversion
Common Stock
2018-10-01$1.45/sh+3,000$4,347→ 8,928 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-10-01−3,000→ 13,220 totalExercise: $1.45Exp: 2024-02-27→ Common Stock (3,000 underlying)
Footnotes (2)
- [F1]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F2]100% of the shares subject to the option are fully vested and exercisable.